Nuclera Launches GPCR Nanodisc Panel to Accelerate Membrane Protein Production for Drug Discovery

Nuclera's new GPCR nanodisc panel enables 48-hour production of active membrane proteins, overcoming major hurdles in pharmaceutical research and development.

By: AXL Media

Published: Mar 30, 2026, 8:33 AM EDT

Source: Information for this report was sourced from Nuclera

The Strategic Shift Toward Rapid GPCR Production

The biotechnology sector faces a persistent challenge in the synthesis of G-Protein Coupled Receptors, which are vital for pharmaceutical development but notoriously difficult to stabilize. Nuclera has addressed this hurdle by launching a dedicated nanodisc panel aimed at enhancing the screening and scale-up of these complex membrane proteins. By utilizing the company’s eProtein Discovery workflow, researchers can now move from initial design to the production of active proteins in just two days. This development is positioned to significantly reduce the time required for early-stage drug discovery, where the availability of high-quality protein samples is often the primary limiting factor.

Overcoming Limitations of Traditional Detergent Micelles

For decades, scientists have relied on cell-based detergent micelles to solubilize membrane proteins, though this method frequently results in non-native conformations that lack biological functionality. According to technical specifications from Nuclera, nanodiscs offer a superior alternative by providing a soluble membrane bilayer that mimics native-like conditions. This environment helps maintain the structural integrity and in vivo functionality of the protein, which is critical for accurate drug screening. The new panel includes eight specific nanodisc combinations, allowing scientists to fine-tune the membrane scaffold proteins and lipid compositions to meet the unique requirements of their therapeutic targets.

Integration of Cell-Free Synthesis and Co-Translational Insertion

The technical core of this launch lies in the integration of pre-assembled nanodiscs directly into a cell-free protein synthesis approach. This methodology enables the co-translational insertion of nascent proteins, which essentially allows the protein to fold into its active form as it is being created. According to Dr. Michael Chen, CEO of Nuclera, this integrated capability equips researchers with a powerful approach to increase success rates when expressing active GPCRs. By avoiding the stresses of traditional cell-based production, the system delivers higher yields of soluble proteins that are more stable for essential downstream applications, such as structural biology and ligand binding assays.